Side-by-side comparison
Gilead Sciences vs Eli Lilly and
As of Sep 25, 2026, P/S is 6.1x for Gilead Sciences vs 14.0x for Eli Lilly and; revenue growth is 5.5% for Gilead Sciences vs 49.6% for Eli Lilly and; net margin is -10.6% for Gilead Sciences vs 33.5% for Eli Lilly and; debt/equity is 2.01 for Gilead Sciences vs 1.41 for Eli Lilly and.
Key metrics
| Metric | GILD | LLY |
|---|---|---|
| Price | $150.93 | $1,183.46 |
| Market cap | $187.15B | $1.11T |
| P/E | — | 39.7x (#1) |
| P/S | 6.1x (#1) | 14.0x (#2) |
| Revenue growth | 5.5% (#2) | 49.6% (#1) |
| Operating margin | -8.2% (#1) | — |
| Net margin | -10.6% (#2) | 33.5% (#1) |
| Debt / equity | 2.01 (#2) | 1.41 (#1) |
| 1-year return | +34.6% (#2) | +63.3% (#1) |
| Research score | 42/100 (#2) | 69/100 (#1) |
Higher is better for growth, margins, one-year return and overall score; lower is better for valuation and debt ratios. Ties share a rank and missing values are excluded.
Company research
- Gilead Sciences, Inc. (GILD) — Drug Manufacturers—General
- Eli Lilly and Company (LLY) — Drug Manufacturers—General